INOVIO PHARMACEUTICALS, INC. (INO)

1.15 0.02 (1.77%)

As of 2026-04-02 18:56:05 EST

Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).

Traded asNasdaq: INO
ISINUS45773H4092
CIK0001055726
LEI529900B9W875XDZXTM97
EIN330969592
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOJacqueline Shea, Ph.D.
Employees262
Fiscal Year End1231
Address660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
Phone8584103134
Websitehttps://www.inovio.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
INOINOVIO PHARMACEUTICALS, INC.2026-04-02 18:56:051.150.021.77
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
INO0001055726INOVIO PHARMACEUTICALS, INC.US45773H4092529900B9W875XDZXTM97330969592Nasdaq2834Pharmaceutical Preparations1231DE660 W. GERMANTOWN PIKEPLYMOUTH MEETINGPA19462UNITED STATESUS8584103134660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462INOVIO BIOMEDICAL CORPBiotechnology1999Jacqueline Shea, Ph.D.262https://www.inovio.com74,300,00068,996,64769,091,956Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).2026-04-02 19:12:24
This is a preview of the latest data. Subscribe to access the full data.
INO Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
INO Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202574,300,000-133,700,000-64.278869,091,95632,424,73588.4298
2024208,000,00088,300,00073.767836,667,22113,296,85656.8962
2023119,700,000-305,800,000-71.868423,370,365-236,761,621-91.016
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Peter D. KiesChief Financial Officer2024506,8060131,957—15,204940,072
Jacqueline E. SheaChief Executive Officer, President2024728,0000490,819—15,1692,050,669
Michael Sumner, M.D.Chief Medical Officer2024532,00047,133139,596—15,2501,037,406
Peter D. KiesChief Financial Officer2023622,8810132,252—15,0001,161,040
Jacqueline E. SheaChief Executive Officer, President2023750,6150491,873—12,1412,438,908
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2025112
2024134
2023122
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue65,343217,756832,010
Cost Of Revenue———
Gross Profit———
Research And Development Expenses54,206,87475,620,34086,676,563
General And Administrative Expenses32,680,57336,996,33847,582,104
Operating Expenses86,887,447112,616,678144,772,038
Operating Income-86,822,104-112,398,922-143,940,028
Net Income-84,945,901-107,254,126-135,117,352
Earnings Per Share Basic-1.81-3.95-6.09
Earnings Per Share Diluted-1.81-3.95-6.09
Weighted Average Shares Outstanding Basic46,886,41327,160,86322,173,662
Weighted Average Shares Outstanding Diluted46,886,41327,160,86322,173,662
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents44,273,31965,813,29714,310,862
Marketable Securities Current14,239,14528,300,232130,982,913
Accounts Receivable4501,199,0560
Inventories———
Non Trade Receivables———
Other Assets Current———
Total Assets Current61,123,34697,830,050153,113,100
Marketable Securities Non Current———
Property Plant And Equipment2,527,6033,659,8184,960,986
Other Assets Non Current2,012,4751,979,654605,315
Total Assets Non Current13,186,68915,367,15617,838,323
Total Assets74,310,035113,197,206170,951,423
Accounts Payable11,053,61816,200,01319,847,744
Deferred Revenue———
Short Term Debt———
Other Liabilities Current———
Total Liabilities Current43,668,55535,325,58442,570,228
Long Term Debt——0
Other Liabilities Non Current———
Total Liabilities Non Current6,545,2049,367,82711,032,066
Total Liabilities50,213,75944,693,41153,602,294
Common Stock68,99736,09922,792
Retained Earnings-1,815,165,163-1,730,219,262-1,622,965,136
Accumulated Other Comprehensive Income-637,963-675,667-662,601
Total Shareholders Equity24,096,27668,503,795117,349,129
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization1,417,9131,752,1472,621,649
Share Based Compensation Expense3,755,7886,595,10811,072,486
Other Non Cash Income Expense022,466-317,997
Change In Accounts Receivable—-1,206,172-9,332,988
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets32,821-38,900-78,729
Change In Accounts Payable-6,423,085-3,367,087-45,989,061
Change In Other Liabilities——0
Cash From Operating Activities-88,629,430-104,076,553-124,365,551
Purchases Of Marketable Securities4,946,07354,138,026203,475,052
Sales Of Marketable Securities14,271,128158,637,578284,932,562
Acquisition Of Property Plant And Equipment285,698487,832320,898
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities14,039,357104,071,03987,355,875
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock34,908,59336,033,4735,461,745
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities53,050,09551,475,5464,995,099
Change In Cash-21,539,97851,502,435-32,018,497
Cash At End Of Period44,273,31965,813,29714,310,862
Income Taxes Paid———
Interest Paid0533,4871,066,975
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-1.81-3.95-6.09
Price To Earnings Ratio-0.9613-0.4633-1.005
Earnings Growth Rate-54.1772-35.1396420.5128
Price Earnings To Growth Ratio0.01770.0132-0.0024
Book Value Per Share0.51392.52225.2923
Price To Book Ratio3.38570.72561.1564
Ebitda-83,527,988-105,324,146-131,272,914
Enterprise Value——121,396,384.1724
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio——0
Capital Expenditures285,698450,979-145,362
Free Cash Flow-88,915,128-104,527,532-124,220,189
Return On Equity-3.5253-1.5657-1.1514
One Year Beta0.95481.6391.7806
Three Year Beta1.29261.94821.7357
Five Year Beta1.5180.61720.6299
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Sumner Michael JohnChief Medical Officer2026-03-314,292A34,799
Sumner Michael JohnChief Medical Officer2026-03-311,223D33,576
Sumner Michael JohnChief Medical Officer2026-03-314,292D0
KIES PETERCFO2026-03-0431,240A31,240
KIES PETERCFO2026-03-0425,520A25,520
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
MJT & Associates Financial Advisory Group, Inc.2026-03-315663251.7415
GOLDMAN SACHS GROUP INC2025-12-3147,48127,2881.74
Rockefeller Capital Management L.P.2025-12-313,5442,0371.7398
Caitong International Asset Management Co., Ltd2025-12-3185,17048,9481.74
Virtu Financial LLC2025-12-3177,00044,0401.7484
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Advisors' Inner Circle Fund III2026-01-31I SharesKCXIX266433.580.0001
VICTORY PORTFOLIOS III2026-01-31Victory Extended Market Index FundUSMIX7,00511,418.150.0015
FIDELITY SECURITIES FUND2026-01-31Fidelity Advisor Small Cap Growth Fund: Class ZFIDGX5,980,1949,747,716.220.1243
FIDELITY SECURITIES FUND2026-01-31Fidelity Advisor Small Cap Growth Fund: Class IFCIGX5,980,1949,747,716.220.1243
FIDELITY SECURITIES FUND2026-01-31Fidelity Advisor Small Cap Growth Fund: Class MFCTGX5,980,1949,747,716.220.1243
This is a preview of the latest data. Subscribe to access the full data.